Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)

Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

Family Matters: The central role of the IL-17 family of cytokines in inflammatory diseases